Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Receivables: 2012-2024

Historic Change in Receivables for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $21.7 million.

  • Amphastar Pharmaceuticals' Change in Receivables rose 71.21% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year decrease of 67.33%. This contributed to the annual value of $21.7 million for FY2024, which is 16.92% down from last year.
  • As of FY2024, Amphastar Pharmaceuticals' Change in Receivables stood at $21.7 million, which was down 16.92% from $26.1 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Change in Receivables ranged from a high of $26.1 million in FY2023 and a low of $10.1 million during FY2022.
  • Its 3-year average for Change in Receivables is $19.3 million, with a median of $21.7 million in 2024.
  • In the last 5 years, Amphastar Pharmaceuticals' Change in Receivables soared by 400.81% in 2020 and then plummeted by 32.10% in 2022.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Change in Receivables stood at $20.2 million in 2020, then decreased by 25.99% to $14.9 million in 2021, then slumped by 32.10% to $10.1 million in 2022, then surged by 157.46% to $26.1 million in 2023, then declined by 16.92% to $21.7 million in 2024.